Program
Decitabine
Also written as “decitabine”, “decitabine (5-aza-2'deoxycytidine)” and “IV Decitabine”.
Its studies are mostly in Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Lymphoma, T-Cell, Peripheral · Leukemia, Myeloid, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 90 open or running | phase 4since Nov 5, 2009 | Nov 28, 2005 | none ahead |
| Otsuka | 82 open or running | phase 3since Aug 8, 2002 | Jul 19, 2002 | none ahead |
| EpiDestiny | 30 open or running | phase 1since Jan 31, 2019 | Jan 31, 2019 | none ahead |
| Johnson & Johnson | 30 open or running | phase 2since Aug 29, 2008 | Aug 29, 2008 | none ahead |
| AbbVie | 10 open or running | phase 3since May 3, 2019 | May 3, 2019 | none ahead |
| dong-wha-pharmaceutical-co-ltd | 10 open or running | phase 1since Sep 8, 2017 | Sep 8, 2017 | none ahead |
| Imunopharm Technology | 10 open or running | phase 1since May 14, 2018 | May 14, 2018 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 4since Dec 9, 2013 | Dec 9, 2013 | none ahead |
| Treebough Therapies | 11 open or running | phase 1since May 20, 2025 | May 20, 2025 | Dec 30, 2026phase 1 · NCT07006025 |
Also a collaborator on its studies: dsm-firmenich.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Jul 19, 2002.
- Aug 5, 2010Phase 2 study in Pediatric Acute Myelogenous Leukemia (AML)Eisai · NCT01177540 · 25 enrolled · United States, Australia, Canada
- May 10, 2013Phase 2 study in Leukemia, Myeloid, AcuteJohnson & Johnson · NCT01853228 · 17 enrolled · Belgium, Denmark, France and more
- Dec 9, 2013Sino Biopharmaceutical's first study: phase 4 study in Myelodysplastic SyndromesNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT02013102 · 240 enrolled · China
- Mar 20, 2014Phase 2 study in Myelodysplastic SyndromesOtsuka · NCT02103478 · 130 enrolled · United States, Canada
- Sep 8, 2017dong-wha-pharmaceutical-co-ltd's first study: phase 1 study in Advanced Breast CancerNew to dong-wha-pharmaceutical-co-ltddong-wha-pharmaceutical-co-ltd · NCT03282825 · 18 enrolled · Korea, Republic of
- May 14, 2018Imunopharm Technology's first study: phase 1 study in NHLNew to Imunopharm TechnologyImunopharm Technology · NCT03535753 · 50 enrolled · China
- Jan 31, 2019EpiDestiny's first study: phase 1 study in HealthyNew to EpiDestinyEpiDestiny · NCT03828084 · 16 enrolled · United States
- May 3, 2019AbbVie's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT03941964 · 60 enrolled · United States
- Sep 10, 2019Phase 1 study in HealthyEpiDestiny · NCT04086238 · 46 enrolled · United States
- May 23, 2022Phase 1 study in Lymphoma, T-Cell, PeripheralOtsuka · NCT05403450 · 33 enrolled · United States, Australia, France and more
- Mar 31, 2023Phase 1 study in HealthyEpiDestiny · NCT05816356 · 10 enrolled · United States
- Apr 25, 2023Phase 3 study in Myelodysplastic SyndromesOtsuka · NCT05883956 · 13 enrolled · Australia, New Zealand
- Sep 22, 2023Phase 2 study in Myelodysplastic SyndromesOtsuka · NCT06091267 · 72 enrolled · China
- May 20, 2025Treebough Therapies's first study: phase 1 study in MDSNew to Treebough TherapiesTreebough Therapies · NCT07006025 · 20 planned · United States
Ahead
- Dec 30, 2026Primary completion: phase 1 study in MDSTreebough Therapies · NCT07006025
TargetBeta
“DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07006025MDS · United States | 1 | Recruiting | Treebough Therapies | Dec 30, 2026 | 20 |
| NCT06091267Myelodysplastic Syndromes · China | 2 | Active, not recruiting | Otsuka | May 22, 2026 | 72 |
| NCT05883956Myelodysplastic Syndromes · Australia, New Zealand | 3 | Active, not recruiting | Otsuka | Dec 6, 2024 | 13 |
| NCT05816356Healthy · United States | 1 | Completed | EpiDestiny | Jun 30, 2023 | 10 |
| NCT05403450Lymphoma, T-Cell, Peripheral · United States, Australia, France and more | 1 | Terminated | Otsuka | Dec 16, 2024 | 33 |
| NCT04086238Healthy · United States | 1 | Completed | EpiDestiny | Nov 21, 2019 | 46 |
| NCT03941964Leukemia, Myeloid, Acute · United States | 3 | Completed | AbbVie | Mar 14, 2022 | 60 |
| NCT03828084Healthy · United States | 1 | Completed | EpiDestiny | May 2, 2019 | 16 |
| NCT03535753NHL · China | 1 | UNKNOWN | Imunopharm Technology | Sep 1, 2020 | 50 |
| NCT03282825Advanced Breast Cancer · Korea, Republic of | 1 | UNKNOWN | dong-wha-pharmaceutical-co-ltd | Feb 2018 | 18 |
| NCT02103478Myelodysplastic Syndromes · United States, Canada | 2 | Completed | Otsuka | Jun 5, 2018 | 130 |
| NCT02013102Myelodysplastic Syndromes · China | 4 | UNKNOWN | Sino Biopharmaceutical | Dec 2015 | 240 |
| NCT01853228Leukemia, Myeloid, Acute · Belgium, Denmark, France and more | 2 | Terminated | Johnson & Johnson | Aug 28, 2017 | 17 |
| NCT01177540Pediatric Acute Myelogenous Leukemia (AML) · United States, Australia, Canada | 2 | Terminated | Eisai | Jul 19, 2013 | 25 |
| NCT01011283Myelodysplastic Syndromes · United States | 4 | Terminated | Eisai | Jan 2011 | 26 |
| NCT00941109Myelodysplastic Syndromes · United States | 1 | Completed | Eisai | Sep 2011 | 12 |
| NCT00796003Myelodysplastic Syndromes · Japan | 1 | Completed | Johnson & Johnson | Oct 2010 | 39 |
| NCT01378416Leukemia · United States | 1 | Completed | Eisai | Jan 2006 | 16 |
| NCT00760084Leukemia, Myeloid, Acute · United States | 2 | Completed | Eisai | Sep 2005 | 10 |
| NCT00744757Myelodysplastic Syndromes · Taiwan | 2 | Completed | Johnson & Johnson | Sep 2010 | 37 |
| NCT00619099Myelodysplastic Syndromes · United States | 2 | Completed | Eisai | Mar 2012 | 67 |
| NCT00358644Leukemia, Myeloid, Acute · United States | 2 | Completed | Eisai | Feb 2008 | 55 |
| NCT00282399Myelodysplastic Syndromes · United States | 1 | Terminated | Eisai | Oct 2008 | 41 |
| NCT00260065Myelodysplastic Syndromes · United States, Canada | 2 | Completed | Eisai | Jun 2008 | 99 |
| NCT00043381Myelodysplastic Syndromes · United States | 3 | Completed | Otsuka | Nov 2002 | 160 |
| NCT00042016Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 2 | Completed | Otsuka | 40 | |
| NCT00042003Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 2 | Completed | Otsuka | Dec 2004 | 40 |
| NCT00041990Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 2 | Completed | Otsuka | 40 |
How it is read
Names in the registry
- “Decitabine”, 14 entries
- “decitabine”, 8 entries
- “decitabine (5-aza-2'deoxycytidine)”, 4 entries
- “IV Decitabine”, 1 entry
- “Decitabine + Cedazuridine”, 1 entry
Conditions, from the studies’ own filings
- Myelodysplastic Syndromes, 13 studies
- Leukemia, Myeloid, Acute, 7 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
- Lymphoma, T-Cell, Peripheral, 1 study
- Leukemia, Myeloid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.